- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
May 14, 2020
As the COVID-19 pandemic rages on across the world, the latest crisis is markedly reminiscent of the early days of HIV. And while the HIV epidemic is far from over, unrelenting activism, strong community engagement, partnerships and innovation are to thank for the strides the field has made towards controlling the epidemic.
Now, the response to COVID-19 is drawing heavily from these successes, and at the same time, forcing even more innovation on the HIV front.
In this episode of Px Pulse, we’ve compiled excerpts from two April webinars that offer unique perspectives on how COVID-19 and HIV are shaping one another. First, Mark Feinberg, CEO of IAVI, and Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI), speak to COVID-19 vaccine development, and the role of the Coalition for Epidemic Preparedness Innovation (CEPI) in spurring vaccine funding and collaboration. We then turn to community engagement experts Sinead Delany-Moretlwe, Director of Research at Wits RHI, Vincent Basajja of the Uganda Virus Research Institute, Jau Nanyondo from Uganda’s Makerere University Walter Reed Project and Philister Adhiambo from the Kenya Medical Research Institute, who explain how HIV prevention trials are adapting in the wake of COVID-19.
Listen
Highlights
- IAVI’s Mark Feinberg on how HIV pioneered strategies now deployed against COVID-19 (6:21)
- Wits RHI’s Helen Rees on collaborations, such as CEPI, responding to COVID-19 and future (3:13)
- Wits RHI’s Sinead Delany-Moretlwe on the implications of COVID-19 on HIV prevention trials (3:13)
- Vincent Basajja of the Uganda Virus Research Institute, Jau Nanyondo from Uganda’s Makerere University Walter Reed Project and Philister Adhiambo from the Kenya Medical Research Institute on the challenges of adapting trials in the context of COVID-19 (5:02)
Additional Resources
- AVAC webinars on COVID-19 and HIV: The Impact of COVID-19 on Clinical Trials in Sub-Saharan Africa; Pandemic Vaccine Development and Lessons for COVID-19 – AVAC
- COVID-19 Resources for Advocates – AVAC
- COVID-19 Implications on HIV Prevention Trials – AVAC
- Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus – AVAC
- Op-ed: COVID-19: The HIV research advocacy offers lessons – Science Speaks